TESTICULAR CANCER Updated March 2016 by Dr. Safiya Karim (PGY-5 Medical Oncology Resident, University of Toronto)
|
|
- Dustin Blake
- 6 years ago
- Views:
Transcription
1 TESTICULAR CANCER Updated March 2016 by Dr. Safiya Karim (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Aaron Hansen (Staff Medical Oncologist, University of Toronto) DISCLAIMER: The following are study notes compiled by the above PGY-5 medical oncology residents and reviewed by a staff medical oncologist. They reflect what we feel is relevant knowledge for graduating medical oncology residents preparing for their final examination. The information has not been surveyed or ratified by the Royal College. A) PUBLIC HEALTH EPIDEMIOLOGY - Incidence: 8,720 cases estimated in the US (2016) - Mortality: Highly treatable, often curable, 5 year relative survival rate = 97% RISK FACTORS - Environmental/Chemical/Infections: cryptorchidism, germ cell neoplasia in situ, hypospadias, contralateral testicular cancer, extragonadal germ cell tumor, HIV infection, - Genetic: Family history of testicular cancer, Kleinfelter s syndrome, Down syndrome, Peutz- Jeghers syndrome, Carney s complex PREVENTION & SCREENING - Prevention: Surgical correction of cryptorchidism - Screening: Nil B) PRESENTATION & DIAGNOSIS SYMPTOMS & SIGNS - Common Symptoms: painless testicular swelling/ nodule, dull ache in lower abdomen, back pain - Common Signs: o Localized: painless testicular swelling/ nodule, gynecomastia o Metastatic: neck mass, lower extremity swelling - Common Presentations: painless testicular swelling/ nodule, acute painful testes, neck mass, pulmonary mass INVESTIGATIONS - Laboratory: CBC, extended electrolytes, liver enzymes, AFP, B-HCG, LDH - Diagnostic Imaging: scrotal ultrasound, CXR +/- CT chest, CT abdo/pelvis - Diagnostic Procedures: radical inguinal orchiectomy, PATHOLOGY & MOLECULAR BIOLOGY - Common Histology: o o Seminomas Non-seminoma! Embryonal carcinomas! Teratomas! Yolk sac tumors! Choriocarinomas - Common Metastatic Sites: Retroperitoneal lymph nodes, lungs, - Less Common Metastatic Sites: Bone, liver, brain - Relevant Molecular Biology: N/A
2 STAGING - TNM Primary tumour (T) ptx Primary tumour cannot be assessed pt0 No evidence of primary tumour (e.g. histologic scar in testis) ptis Intratubular germ cell neoplasia (carcinoma in situ) pt1 Tumour limited to the testis and epididymis without vascular/lymphatic invasion; tumour may invade into the tunica albuginea but not the tunica vaginalis pt2 Tumour limited to the testis and epididymis with vascular/lymphatic invasion, or tumour extending through the tunical albuginea with involvement of the tunica vaginalis pt3 Tumour invades the spermatic cord with or without LVI pt4 Tumour invades the scrotum with or without LVI Regional lymph nodes (N) Clinical NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Metastasis with a lymph node mass 2cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension N2 Metastasis with a lymph node more than 2cm but not more than 5cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2cm but not more than 5cm in greatest dimension N3 Metastasis with a lymph node mass >5cm Pathological (pn) pnx Regional lymph nodes cannot be assessed pn0 No regional lymph node metastasis pn1 Metastasis with a lymph node mass 2cm or less in greatest dimension and less than or equal to five nodes positive, none more than 2cm in greatest dimension pn2 Metastasis with a lymph node mass more than 2cm but not more than 5cm in greatest dimension; or more than five nodes positive, none more than 5cm; or evidence of extranodal extension of tumour pn3 Metastasis with a lymph node mass more than 5cm in greatest dimension Distant metastasis (M) M0 No distant metastasis M1 Distant metastasis M1a Nonregional nodal or pulmonary metastasis M1b Distant metastasis other than to nonregional lymph nodes and lung Serum tumour markers (S) SX Marker studies not available or not performed S0 Marker study levels within normal limits S1 LDH <1.5 x ULN AND HCG <5000 IU/L AND AFP <1000 ug/l S2 LDH x ULN or hcg ,000 or AFP ,000 S3 LDH >10 x ULN or hcg > 50,000 or AFP > 10,000 Stage T N M S 0 ptis N0 M0 S0 I pt1-4 N0 M0 SX IA pt1 N0 M0 S0 IB pt2 N0 M0 S0 pt3 N0 M0 S0 pt4 N0 M0 S0 IS Any pt/tx N0 M0 S1-3 II Any pt/tx N1-3 M0 SX
3 IIA Any pt/tx N1 M0 S0 Any pt/tx N1 M0 S1 IIB Any pt/tx N2 M0 S0 Any pt/tx N2 M0 S1 IIC Any pt/tx N3 M0 S0 Any pt/tx N3 M0 S1 III Any pt/tx Any N M1 SX IIIA Any pt/tx Any N M1a S0 Any pt/tx Any N S1 IIIB Any pt/tx N1-3 M0 S2 Any pt/tx Any N M1a S2 IIIC Any pt/tx N1-3 M0 S3 Any pt/tx Any N M1a S3 Any pt/tx Any N M1b Any S - IGCCC Risk Classification for advanced disease Classification Nonseminoma Seminoma Good risk Gonadal or retroperitoneal primary tumour No nonpulmonary visceral metastasis Good tumour markers (AFP <1000ug/L and hcg <5000 IU/L and LDH <1.5 x N) Any primary site No nonpulmonary visceral metastasis Normal AFP, any hcg, any Intermediate risk Poor risk Gonadal or retroperitoneal primary tumour No nonpulmonary visceral metastasis Intermediate tumour markers (AFP < ,000 ug/l or hcg < IU/L or LDH < x N) Mediastinal primary tumour or Nonpulmonary visceral metastasis or Poor tumour markers (AFP >10,000 ug/l or hcg >50,000 IU/L or LDH >10 x N) LDH Any primary site Nonpulmonary visceral metastasis Normal AFP, any hcg, any LDH N/A C) TREATMENT Early Stage Disease: Stage I Seminoma: - Bottom Line General Approach: orchiectomy followed by surveillance or chemotherapy (1-2 cycles of carboplatin) - Prognosis: cure rate approaches 100% regardless of whether any post orchiectomy adjuvant therapy is given, 10-yr recurrence rate = 15-20% Stage II Seminoma: - Bottom Line General Approach: Stage IIa: orchiectomy followed by RT or chemotherapy (BEP x 3 cycles) Stage IIb/c: orchiectomy followed by chemotherapy (BEP x 3 cycles) - Prognosis: 5 year disease free survival of >90% for stage IIa and non-bulky stage IIb disease Important Phase III Clinical Trials:
4 Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial (ISRCTN ) Jones, WG et al. J Clin Oncol Feb 20; 23(6): Regimen 20 Gy/ 10 fractions vs. 30 Gy/ 15 fractions Mechanism of N/A Primary Endpoint Relapse free rate Secondary endpts: morbidity and quality of life Inclusion/Exclusion Stage 1 seminoma following orchiectomy pt4 tumors excluded Size (N) 625 patients Results 2 year relapse free rate: 97.7% (30 Gy) vs 97 % (20 Gy) Quality of Life: trend towards higher rates of nausea and vomiting in the 30 Gy group, higher rates of moderate to severe lethargy and inability to work in the 30 Gy group Toxicity Nausea/ vomiting, leucopenia, thrombocytopenia Conclusion 20 Gy/ 10 fractions is unlikely to produce relapse rates higher than 3% and provides reduction in morbidity Other Comments Higher risk of second malignancies Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC study (ISRCTN ) Oliver, RT et al. J Clin Oncol Mar 10; 29(8): Regimen RT (30 Gy/15 or 20 Gy/10) vs. carboplatin AUC 7 x 1 dose Non-inferiority design Mechanism of Carboplatin causes the intra- and inter-strand cross-linkage of DNA molecules within the cell. This modifies the DNA structure and inhibits DNA synthesis. Primary Endpoint Relapse free rates Inclusion/Exclusion Stage 1 seminoma post orchiectomy Size (N) 1477 patients Results 5 year Relapse free rate: 94.7% (carboplatin) vs 96.0% (RT), HR 1.25, p=0.37 Risk of contralateral germ-cell tumor: significantly decreased with carboplatin vs RT, HR 0.22, p=0.03 Toxicity Not reported Conclusion Carboplatin x 1 dose (AUC 7) is non-inferior to adjuvant RT and reduces the risk of contralateral germ-cell tumors Other Comments Stage I non-seminoma: - Bottom Line General Approach: radical orchiectomy followed by surveillance - At some centers retroperitoneal lymph node dissection (RPLND) or chemotherapy (BEP x 1 or 2 cycles is done but this is not routine - Prognosis: Disease free survival of ~99%. 70% cure rate with orchiectomy alone; 30% relapse rate
5 Stage II non-seminoma: - Bottom Line General Approach: radical orchiectomy followed by RPLND +/- chemotherapy If Stage IIb/c radical orchiectomy followed by chemo (BEP x 3) (with resection of residual masses) or RPLND (followed by BEP x 3 if active malignanct in resection) Prognosis: 95% cure rate - Important Phase III Clinical Trials: Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group Albers, P et al. J Clin Oncol Jun 20; 26(18): Regimen Retroperitoneal lymph node dissection (RPLND) vs BEP x 1 cycle post orchiectomy (bleomycin 30mg d1,8,15, etoposide 100mg/m2 day 1-5), cisplatin 20mg/m2 day 1-5) Mechanism of Primary Endpoint Rate of recurrence Inclusion/Exclusion Stage 1 non-seminoma post orchiectomy Excluded if LN > 10mm in transverse diameter Size (N) 382 patients Results 2 year difference in recurrence free rate: 7.59% in favor of chemotherapy Toxicity Grade 3 hematologic toxicities seen in 37.4% of patients receiving 1 cycle of BEP Neutropenic fever in only 4 patients receiving 1 cycle of BEP Conclusion 1 cycle of BEP is superior to RPLND in patients with stage 1 nonseminoma post orchiectomy Other Comments A significant number of patients on the RPLND arm received 2 BEP. This trial has been criticized for the poor quality of surgery in the RPLND arm. Hence this trial should be very interpreted cautiously. ADVANCED DISEASE
6 - Bottom Line General Approach: Treatment determined on basis of prognosis (good, intermediate, poor risk) o Good risk disease: BEP x 3 or EP x 4 (if bleomycin contraindicated) o Intermediate/ poor risk disease: BEP x 4 or VIP x 4 (if bleomycin contraindicated) - Prognosis: o Good risk: > 95% cause specific survival o Intermediate risk: ~75-80% cause specific survival o Poor risk: 50-60% cause specific survival - Important Phase III Clinical Trials: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide Williams, SD et al. NEJM Jun 4; 316(23): Regimen Cisplatin+ etoposide+ bleomycin (BEP) vs cisplatin + vinblastine + bleomycin (PVB) Mechanism of Vinblastine produces significant neuromuscular toxicity Use of etoposide would prevent development of neuromuscular toxicity Primary Endpoint Disease free survival Inclusion/Exclusion Men with disseminated germ cell tumors Size (N) 244 patients Results DFS: 83% (BEP) vs. 74% (PVB) p = not significant In patients with high tumor volume: 77% vs 61% DFS OS: Increased in patients on etoposide Fewer parasthesias, abdominal cramps and myalgias with etoposide Toxicity Similar rates of myelosuppresive effects and pulmonary toxicity Conclusion BEP is superior to PVB due to diminished neuromuscular toxicity and increased efficacy in patients with high tumor volume Other Comments Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council De Wit, R et al. J Clin Oncol Mar 15; 19(6): Regimen BEP x 4 cycles vs BEP x 3 cycles and 5 day vs. 3 day regimen (2x2 factorial trial) Mechanism of Primary Endpoint 2 year PFS Inclusion/Exclusion Good prognosis germ cell tumors post orchiectomy Size (N) 812 patients Results 2 year PFS: 90.4% (3 cycles) vs. 89.4% (4 cycles) 88.8% (5 day regimen) vs. 89.7% (3 day regimen) Quality of Life: Better maintained with 3 cycle vs 4 cycle regimen; no difference between 5 day vs 3 day regimen Toxicity Similar rates of hematologic and non-hematologic toxicites Conclusion 3 cycles of BEP is sufficient therapy in good prognosis germ cell tumors and administration of chemotherapy over 3 days has no
7 Other Comments detrimental effect Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. Nichols, CR et al. J Clin Oncol Apr; 16(4): Regimen Bleomycin, Etoposide and Cisplatin (BEP) x 4 cycles vs Etoposide, Ifosfomide and Cisplatin (VIP) x 4 cycles Mechanism of Primary Endpoint Overall survival Inclusion/Exclusion Poor and intermediate risk germ cell tumors post orchiectomy Size (N) 304 patients Results 2 year OS: BEP 71% vs VIP 74% Overall complete remission rate: BEP 31% vs VIP 37% Failure free at 2 years: BEP 60% vs VIP 64% Toxicity Higher rates of grade 3+ hematologic and genitourinary toxicity with VIP Conclusion 4 cycles of VIP produce similar response rates and survival to 4 cycles of BEP with increased toxicity. Other Comments Patients intolerant or not candidates for bleomycin are treated with VIP Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors Motzer RJ et al. J Clin Oncol Jan 20; 25(3): Regimen 4 cycles of bleomycin, etoposide and cisplatin (BEP) vs. 2 cycles of BEP + high dose chemotherapy containing carboplatin followed by hematopoetic stem cell rescue (BEP + HDCT) Mechanism of High-dose chemotherapy (HDCT) was studied in single-arm phase II trials as first-line therapy for patients with poor-prognostic features The relative tolerability and improvement in relapse-free survival and overall survival (OS) compared with historical controls treated with conventional-dose programs suggested that this was a promising approach Primary Endpoint Durable CR at 1 year Inclusion/Exclusion Poor and intermediate risk germ cell tumors post orchiectomy Size (N) 219 patients Results 1 year durable CR: BEP 52% vs BEP + HDCT 48%, p=0.53 Median time to treatment failure: BEP: 11.3 months vs BEP + HDCT 23.2 months, p=0.4 Toxicity Higher rates of grade 3+ neurologic, GI and hepatobiliary toxicity in BEP + HDCT arm Conclusion The routine inclusion of HDCT in first-line treatment for GCT patients with metastases and a poor predicted outcome to chemotherapy did not improve treatment outcome
8 Other Comments Patients with slow serum tumor marker decline (alpha-fetoprotein and/or human chorionic gonadotrophin) during the first two cycles of chemotherapy had a shorter progression-free survival and overall survival compared with patients with satisfactory marker decline (P =.02 and P =.03, respectively). Among 67 patients with unsatisfactory marker decline, the 1-year durable complete response proportion was 61% for patients who received HDCT versus 34% for patients receiving BEP alone (P =.03) MANAGEMENT OF RESIDUAL MASSES FOLLOWING CHEMOTHERAPY Residual disease in seminomas: Residual masses are often fibrotic but may contain residual seminoma 3 main options: o observation with no additional treatment or biopsy unless mass is growing o o observation of masses <3cm and PET scan for masses > 3cm PET scan 2 months after completion of chemotherapy. If PET negative, no further scans. If PET positive, consider surgical resection or if tumor has responded but still above 3 cm then consider observation 5 Residual disease in non-seminomas: > 1cm: o Most often contain residual tumor or teratoma o Standard of care is to resect all residual masses however there are no randomized trials to validate this approach <=1cm: o Area of controversy o Observe vs RPLND o If RPLND shows fibrosis, necrosis or mature teratoma " no further therapy o If RPLND positive for viable cancer, observation vs. chemotherapy (usually EP) x 2 cycles D) REFERENCES 1. Beard, CJ and Oh, WK. Treatment of stage II seminoma. In Kantoff, PW and Ross, ME (Eds): UpToDate. Retrieved from 2. Gilligan, TD and Kantoff, PW. Initial risk stratified treatment for advanced testicular germ cell tumors. In Oh, WK and Ross, ME (Eds). UpToDate. Retrieved from 3. PDQ Adult Treatment Editorial Board. Testicular Cancer Treatment (PDQ ): Health Professional Version Feb 17. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); Available from: 4. Oh, WK. Overview of the treatment of testicular germ cell tumors. In Kantoff, PW and Ross, ME (Eds): UpToDate. Retrieved from 5. De Santis et al fluoro-deoxy-d-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial. J Clin Oncol. 2004; 22(6):
9
EAU GUIDELINES ON TESTICULAR CANCER
EAU GUIDELINES ON TESTICULAR CANCER (Limited text update March 2018) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna (Vice-chair), N. Nicolai,
More informationEAU GUIDELINES ON TESTICULAR CANCER
EAU GUIDELINES ON TESTICULAR CANCER (Limited text update March 2015) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg
More informationEAU GUIDELINES ON TESTICULAR CANCER
EU GUIDELINES ON TESTICULR CNCER (Limited text update March 2017) P. lbers (Chair), W. lbrecht, F. lgaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi,. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg Introduction
More informationTesticular Malignancies /8/15
Collecting Cancer Data: Testis 2014-2015 NAACCR Webinar Series January 8, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationGUIDELINES ON TESTICULAR CANCER
38 (Text updated March 2005) P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, A. Horwich, O. Klepp, M.P. Laguna, G. Pizzocaro Introduction Compared with other types of cancer
More informationCase Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult
Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was
More informationCase Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult
Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was
More informationTestis. Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies.
Testis Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies. Protocol revision date: January 2005 Based on AJCC/UICC
More informationQuiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.
Quiz 1 Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios. 1. 62 year old Brazilian female Race 1 Race 2 Spanish/Hispanic Origin 2. 43 year old Asian male born in Japan Race 1
More informationExercise. Discharge Summary
Exercise Discharge Summary A 32-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was present
More informationTesticular germ cell tumors
Testicular germ cell tumors Introduction Most common solid tumor in young adult men with 3 6 new cases/100,000 men/year. They acc ount for 1.5% of male malignancies and 5% of urological tumors. Bilateral
More informationNICaN Testicular Germ Cell Tumours SACT protocols
Reference No: Title: Author(s) Ownership: Approval by: Systemic Anti-Cancer Therapy (SACT) Guidelines for Germ Cell Tumours Dr Audrey Fenton Consultant Medical Oncologist, Dr Vicky Coyle Consultant Medical
More informationFellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates
More informationFellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates
More informationResection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer
Turkish Journal of Cancer Vol.31/ No. 2/2001 Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer AHMET ÖZET 1, ALİ AYDIN YAVUZ 1, MURAT BEYZADEOĞLU
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationGerm Cell Tumors. Karim Fizazi, MD, PhD Institut Gustave Roussy, France
Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Surveillance for stage I GCT NSGCT A 26 year-old patient had a orchiectomy revealing embryonal carcinoma (40%), seminoma (40%) and
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation in the Treatment of Germ File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_in_the_treatment_of_germ_cell_tumor
More informationGuidelines on Testicular Cancer
Guidelines on Testicular Cancer P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna European Association of Urology 2009 TABLE OF CONTENTS
More informationPoor-prognostic advanced Germ Cell Tumors
14-10-16 Poor-prognostic advanced Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Metastatic GCT: Prognosis (IGCCC) Good prognosis Intermediate prognosis Poor prognosis J Clin Oncol
More informationGUIDELINES ON TESTICULAR CANCER
European Association of Urology GUIDELINES ON TESTICULAR CANCER P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, A. Horwich, O. Klepp, M.P. Laguna, G. Pizzocaro UPDATE MARCH
More informationMULTIDISCIPLINARY GENITOURINARY ONCOLOGY COURSE
MULTIDISCIPLINARY GENITOURINARY ONCOLOGY COURSE Case 2 Testicular Cancer Nuno Sineiro Vau Medical Oncologist Champalimaud Foundation, Lisbon October 2017 Male, 36 year-old, sales manager. Past medical
More informationANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY
ANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY Note: These surveillance recommendations are provided as recommendations only. Clinicians should take into account
More informationCardiff MRCS OSCE Courses Testicular Cancer
Testicular Cancer Scenario: A 40-year-old male presents to the surgical out-patient clinic with a 6-8 week history of a painless lump in his left scrotum. He however complains of a dull ache in the scrotum
More informationTesticular Cancer. J. Richard Auman, MD. James J. Stark, MD. Jerry Singer, MD. September 19, 2008
Testicular Cancer J. Richard Auman, MD James J. Stark, MD Jerry Singer, MD September 19, 2008 Testicular Cancer From mystery to far-advanced disease: a remarkable case Case Presentation. 23 y. o. male
More informationPopulations Interventions Comparators Outcomes Individuals: With previously untreated germ cell tumors
Hematopoietic Cell Transplantation in the Treatment of Germ Cell (80135) (Formerly Hematopoietic Stem Cell Transplantation in the Treatment of Germ Cell ) Medical Benefit Effective Date: 04/01/13 Next
More informationCollecting Cancer Data: Testis 2/3/11. Collecting Cancer Data: NAACCR Webinar Series 1. Agenda. Fabulous Prizes
Collecting Cancer Data: Testis February 3, 2011 NAACCR 2010-2011 Webinar Series Agenda Coding moment Race/Hispanic origin Overview Collaborative Stage Treatment Exercises Fabulous Prizes NAACCR 2010-2011
More informationPage 1 of 17 TABLE OF CONTENTS
Page 1 of 17 TABLE OF CONTENTS Suspicious Testicular Cancer. Page 2 nseminomatous Germ Cell Tumor (NSGCT): workup and clinical stage Page 3 Seminoma: workup and clinical stage... Page 4 Clinical Stage
More informationESMO Consensus Empfehlungen 2017
ESMO Consensus Empfehlungen 2017 What s old, what s new, what s missing? Jörg Beyer, Klinik für Onkologie Offenlegung Interessenskonflikte 1. Anstellungsverhältnis oder Führungsposition Keine 2. Beratungs-
More informationUncommon secondary tumour of the stomach
Uncommon secondary tumour of the stomach B. Bancel, Hôpital CROIX ROUSSE LYON Bucharest Nov 2013 Case report 33-year old man Profound mental retardation and motor disturbances (sequelae of neonatal meningeal
More informationSTAGING AND FOLLOW-UP STRATEGIES
ATHENS 4-6 October 2018 European Society of Urogenital Radiology STAGING AND FOLLOW-UP STRATEGIES Ahmet Tuncay Turgut, MD Professor of Radiology Hacettepe University, Faculty of Medicine Ankara 2nd ESUR
More informationTwelve Years of Experience in the Management of Testicular Germ Cell Tumors at a Referral Center in Portugal
Elmer Press Original Article Twelve Years of Experience in the Management of Testicular Germ Cell Tumors at a Referral Center in Portugal Diana Valadares a, c, Filipe Nery a, Franklim Marques a, b Abstract
More informationTesticular tumours are uncommon but constitute an
09010:Layout 1 3/18/10 9:26 PM Page E19 CONSENSUS GUIDELINE Canadian consensus guidelines for the management of testicular germ cell cancer Lori Wood, MD; * Christian Kollmannsberger, MD, FRCSC; Michael
More informationViable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection. Can We Predict Patients at Risk of Disease Progression?
2700 Viable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection Can We Predict Patients at Risk of Disease Progression? Philippe E. Spiess, MD 1 Nizar M. Tannir, MD 2 Shi-Ming Tu,
More informationEAU Guidelines on Testicular Cancer
EAU Guidelines on Testicular Cancer P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg Guidelines Associates: J.L.
More information*OPERATIVE PROCEDURE. Serum tumour markers within normal limits S1.04 PRINCIPAL CLINICIAN
Neoplasia of the Testis - Orchidectomy Histopathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous
More informationCitation for published version (APA): Lutke Holzik, M. F. (2007). Genetic predisposition to testicular cancer s.n.
University of Groningen Genetic predisposition to testicular cancer Lutke Holzik, Martijn Frederik IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationWhat is Testicular cancer?
Testicular Cancer What is Testicular cancer? Testicular cancer is a disease in which cancer cells form in the tissues of one or both testicles. The testicles are 2 egg-shaped glands located inside the
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationTeratocarcinoma In A Young Boy- An Unusual Presentation
Human Journals Case Report November 2015 Vol.:2, Issue:1 All rights are reserved by Atia Zaka-ur-Rab et al. Teratocarcinoma In A Young Boy- An Unusual Presentation Keywords: Boy, Testicular Mass, Teratocarcinoma
More informationTesticular cancer and other germ cell tumours. London Cancer Jonathan Shamash
Testicular cancer and other germ cell tumours London Cancer 2018 Jonathan Shamash Background Testicular germ cell tumours are the commonest cancers of young men Overall they are curable but long term side
More information-The cause of testicular neoplasms remains unknown
- In the 15- to 34-year-old age group, they are the most common tumors of men. - include: I. Germ cell tumors : (95%); all are malignant. II. Sex cord-stromal tumors: from Sertoli or Leydig cells; usually
More informationTesticular Cancer: Questions and Answers. Testicular cancer is a disease in which cells become malignant (cancerous) in one or both testicles.
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Testicular Cancer: Questions
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationManagement of Testicular Cancer
Management of Testicular Cancer Christian Kollmannsberger MD FRCPC Clinical Professor Div. of Medical Oncology BC Cancer - Vancouver Cancer Centre Dept. of Medicine, University of British Columbia Associate
More informationGERM-CELL TUMOURS. ESMO Preceptorship on Adolescents and Young Adults with cancer Lugano, May 2018
ESMO Preceptorship on Adolescents and Young Adults with cancer Lugano, 11-12 May 2018 GERM-CELL TUMOURS Giannis Mountzios MSc, PhD Medical Oncology University of Athens School of Medicine Athens, Greece
More informationASYMPTOMATIC COMPLEX TESTICULAR NEOPLASIA ASSOCIATED WITH ORCHIEPIDIDYMITIS. CASE REPORT
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2017 vol. 121, no. 4 SURGERY CASE REPORTS ASYMPTOMATIC COMPLEX TESTICULAR NEOPLASIA ASSOCIATED WITH ORCHIEPIDIDYMITIS. CASE REPORT Ș. Iacob 1, R. Vrînceanu 2,3, B.
More informationManagement of Stage Ic-IV Malignant Ovarian Germ Cell Tumours
Management of Stage Ic-IV Malignant Ovarian Germ Cell Tumours Michael J Seckl Charing Cross Hospital Campus of Imperial College NHS Healthcare Trust Imperial College London, UK 9-12th June 2010 Caravaggio
More informationPrognostic factors of genitourinary tumors: Do we have to care?
Prognostic factors of genitourinary tumors: Do we have to care? Jae Y. Ro, MD, PhD Professor and Director of Surgical Pathology The Methodist Hospital, Weill Medical College of Cornell University, Houston,
More informationNCCN Clinical Practice Guidelines in Oncology. Testicular Cancer V Continue
TOC Clinical in Oncology Testicular Cancer V.2.2010 Continue www.nccn.g Version 2.2010, 04/26/10 2010 National Comprehensive Cancer Netwk, Inc. All rights reserved. These guidelines and this illustration
More informationTesticular Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version December 8, NCCN.org.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2017 December 8, 2016 NCCN.org Continue Version 2.2017, 12/08/16 National Comprehensive Cancer Network, Inc. 2016, All rights
More informationTestis tumors. Richard Epstein
Testis tumors Richard Epstein TKCC/SVH, August 5 2016 Testis cancer - Remains virtually the only solid (nonhaematologic) metastatic tumour that is routinely curable by drug therapy. What we will discuss
More informationNote: The cause of testicular neoplasms remains unknown
- In the 15- to 34-year-old age group, they are the most common tumors of men. - Tumors of the testis are a heterogeneous group of neoplasms that include: I. Germ cell tumors : 95%; all are malignant.
More informationMixed Germ Cell Testis Tumor Presenting with Massive Lung Metastasis
International Archives of Medical Research Volume 10, No.1, pp.21-26, 2018. CASE REPORT RESEARCH Mixed Germ Cell Testis Tumor Presenting with Massive Lung Metastasis Zuhat Urakci 1, Senar Ebinc 1, Ogur
More informationLate recurrence of an embryonal carcinoma of the testis. Case report
Late recurrence of an embryonal carcinoma of the testis. Case report Luminita Gurguta 1 *, Mihai V. Marinca 1, 2 1 Medical Oncology Department, Regional Institute of Oncology, Iasi, Romania, 2 Department,
More informationNCCN Clinical Practice Guidelines in Oncology. Testicular Cancer V Continue.
Clinical in Oncology Testicular Cancer V.1.2010 Continue www.nccn.g TOC * Robert J. Motzer, MD/Chair Þ Memial Sloan-Kettering Cancer Center Neeraj Agarwal, MD Huntsman Cancer Institute at the University
More informationMale Genital Cancers in the US in Frequency of Types
Germ Cell Tumors of the Testis Pathology, Immunohistochemistry, and the Often Confusing Appearance of Their Metastases Charles Zaloudek, MD Department of Pathology UCSF Male Genital Cancers in the US in
More informationmolecular brothers David Pfisterer Lucerne, Switzerland ESIM 2011
molecular brothers David Pfisterer Lucerne, Switzerland ESIM 2011 Case Vignette A 25-year old man was admitted to our hospital because of fever, productive cough, nausea and weight loss. The patient had
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationHematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors (GCT)
Hematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors (GCT) Policy Number: 8.01.35 Last Review: 7/2017 Origination: 7/2002 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationTesticular Cancer. Prof. Dr. Jörg Beyer Physician-in-Chief Department of Oncology, University Hospital Berne, Switzerland. Mail:
Testicular Cancer Prof. Dr. Jörg Beyer Physician-in-Chief Department of Oncology, University Hospital Berne, Switzerland Mail: joerg.beyer@insel.ch The menue: Epidemiology & Staging Ongoing discussions
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationDonamo GU Testis carcinoom. Andre Bergman & Martijn Kerst, 9 september 2015
Donamo GU Testis carcinoom Andre Bergman & Martijn Kerst, 9 september 2015 Casus Ploegarts Tinkoff-Saxo benadert u met de vraag: Is Adjuvante therapie? raadzaam na inguinale orchidectomie vanwege klinisch
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationTesticular Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version November 2, NCCN.org.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2017 November 2, 2016 NCCN.org Continue Panel Members * Timothy Gilligan, MD/Chair Case Comprehensive Cancer Center/ University
More informationTesticular Cancer. What is cancer?
What is cancer? Testicular Cancer The body is made up of trillions of living cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells
More informationBilateral Testicular Germ Cell Tumors
1228 Bilateral Testicular Germ Cell Tumors Twenty-Year Experience at M. D. Anderson Cancer Center Mingxin Che, M.D., Ph.D. 1 Pheroze Tamboli, M.D. 1 Jae Y. Ro, M.D., Ph.D. 1 Dong Soo Park, M.D. 2 Jung
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationLong-Term Outcome for Men With Teratoma Found at Postchemotherapy Retroperitoneal Lymph Node Dissection
Original Article Long-Term Outcome for Men With Teratoma Found at Postchemotherapy Retroperitoneal Lymph Node Dissection Robert S. Svatek, MD 1, Philippe E. Spiess, MD 2, Debasish Sundi, BS 1, Shi-ming
More informationTesticular Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2014 NCCN.org Continue Version 1.2014, 12/13/13 National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN
More informationGerm cell tumors (GCT) are uncommon neoplasms
ORIGINAL ARTICLES: GENERAL THORACIC Pulmonary Metastasectomy for Testicular Germ Cell Tumors: A 28-Year Experience David Liu, MD, Amir Abolhoda, MD, Michael E. Burt, MD, PhD, Nael Martini, MD, Manjit S.
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationBENIGN & MALIGNANT TESTIS DISEASES. Gary J. Faerber, M.D. Associate Professor, Dept of Urology March 2009 OBJECTIVES
BENIGN & MALIGNANT TESTIS DISEASES Gary J. Faerber, M.D. Associate Professor, Dept of Urology March 2009 OBJECTIVES 1. Become familiar with the scrotal contents and their anatomical relationship with each
More informationThe management of low-stage non-seminomatous germ cell tumors
Oncology Reviews 2012; volume 6:e19 The management of low-stage non-seminomatous germ cell tumors Louise Lim, Thomas Powles Department of Medical Oncology, Barts Cancer Institute, QMUL, Experimantal Cancer
More informationRadiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
More informationRunning Title: Utility of HCG Washout in Cervical LND FNA
AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,
More informationPatients and methods. Results
Journal of BUON 10: 195-200, 2005 2005 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Germ cell testicular tumors in clinical stage A and normal values of serum tumor markers post-orchiectomy:
More informationbleomycin, etoposide and cis-platin (BEP)
Br. J. Cancer (1983), 47, 613-619 The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP) M.J. Peckham, A. Barrett, K.H. Liew, A. Horwich, B. Robinson, H.J.
More informationHepatic Resection of Metastatic Testicular Carcinoma: A Further Update
Annals of Surgical Oncology, 6(7):640 644 Published by Lippincott Williams & Wilkins 1999 The Society of Surgical Oncology, Inc. Hepatic Resection of Metastatic Testicular Carcinoma: A Further Update Tara
More informationProf. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich
Prof. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich 32 year old man 2 months history of growing left supraclavicular lymph nodes Antibiotic treatment
More informationTesticular Cancer. Regional Follow-up Guidelines
Urological Cancers Managed Clinical Network Testicular Cancer Regional Follow-up Guidelines Prepared by Drs J White/ A Waterston, J Salmond, J Wallace, Mr D Hendry, Approved by Urological Cancers MCN and
More informationSurveillance Alone Versus Radiotherapy After Orchiectomy for Clinical Stage I Nonseminomatous Testicular Cancer
Surveillance Alone Versus Radiotherapy After Orchiectomy for Clinical Stage I Nonseminomatous Testicular Cancer By Mikael Rorth, Grethe Krag Jacobsen, Hans von der Maase, Ebbe Lindegdrd Madsen, Ole Steen
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationNerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy
Blackwell Science, LtdOxford, UK IJU International Journal of Urology 0919-81722002 Blackwell Science Asia Pty Ltd 910October 2002 520 Postchemotherapy nerve-sparing RPLND N Nonomura et al. 10.1046/j.0919-8172.2002.00520.x
More informationAttachment #2 Overview of Follow-up
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
More informationIntensive Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation During a 10-Year Period in 64 Patients with Germ Cell Tumor
Biology of Blood and Marrow Transplantation 12:355-365 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1203-0013$32.00/0 doi:10.1016/j.bbmt.2005.11.006 Intensive Chemotherapy
More informationLeukaemia 35% Lymphoma 14%
Distribution ib ti of Cancers in Children under 15 years Leukaemia 35% Lymphoma 14% Neuroblastoma 9% Other 5% Liver 1% Retinoblastoma 3% Bone and STS 15% CNS 20% Wilms' 8% 30-40% Mortality Germ Cell Tumours
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationThe Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer
The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer Isidore Mandelbaum, M.D., Peter B. Yaw, M.D., Lawrence H. Einhorn, M.D., Stephen D. Williams,
More informationTestis. Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies.
Testis Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies. Protocol revision date: January 2004 Based on AJCC/UICC
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Testicular Cancer
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2016 NCCN.org Continue Panel Members * Robert J. Motzer, MD/Chair Þ Memorial Sloan Kettering Cancer Center Steven L. Hancock,
More informationHematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors. Original Policy Date
MP 7.03.27 Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature
More informationGERM CELL TUMOUR PI GC-1
GERM CELL TUMOUR PI GC-1 NCCN Pacific Island Working Group Clinical Members Scott Macfarlane Peter Bradbeer Jane Skeen Rob Corbett Radhika Sandilya Page 1 2 TREATMENT OUTLINE 6* cycles of identical treatment
More information